Spots Global Cancer Trial Database for Ruxolitinib for Premalignant Breast Disease
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: Ruxolitinib for Premalignant Breast Disease
Official Title: TBCRC 042 - A Randomized Phase II Window-of-Opportunity Trial of Ruxolitinib in Patients With High Risk and Premalignant Breast Conditions
Study ID: NCT02928978
Study Description
Brief Summary: This study is evaluating how ruxolitinib affects premalignant breast cells. One half of the study participants will receive ruxolitinib for approximately 15 days, and the other half will receive a placebo (sugar pill) for approximately 15 days. Once study participants have completed their ruxolitinib or placebo, participants will undergo surgery to remove the premalignant breast tissue.
Detailed Description:
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
University of Alabama at Birmingham, Birmingham, Alabama, United States
Indiana University Melvin and Bren Simon Cancer Center, Indianapolis, Indiana, United States
Montefiore Medical Center, Bronx, New York, United States
University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, United States
Vanderbilt-Ingram Cancer Center, Nashville, Tennessee, United States
Baylor College of Medicine, Houston, Texas, United States
University of Texas MD Anderson Cancer Center, Houston, Texas, United States
Contact Details
Name: Julie Nangia, M.D.
Affiliation: Baylor College of Medicine
Role: PRINCIPAL_INVESTIGATOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
